AGA2118

DRUG4 trials

Sponsors

Angitia Inc. Ltd., Angitia Biopharmaceuticals, Angitia Incorporated Limited

Conditions

Healthy ParticipantsOsteoporosisPharmacokinetic StudyPostmenopausal Osteoporosis

Phase 1

A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women

CompletedNCT05225857

Angitia BiopharmaceuticalsOsteoporosis

Start: 2022-06-28End: 2024-01-13Updated: 2024-02-05

An Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)

CompletedNCT07361354

Angitia Incorporated LimitedHealthy Participants, Pharmacokinetic Study

Start: 2026-01-05End: 2026-09-05Updated: 2026-09-10

Phase 2

A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)

Active, not recruitingNCT06577935

Angitia BiopharmaceuticalsPostmenopausal Osteoporosis

Start: 2024-10-31End: 2028-03-01Updated: 2026-02-10

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Safety, Tolerability and Efficacy of AGA2118 in Postmenopausal Women with Low Bone Mineral Density

RecruitingCTIS2024-515610-41-00

Angitia Inc. Ltd.Postmenopausal Osteoporosis

Start: 2025-09-11Target: 260Updated: 2025-12-23